Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies.

Full Abstract

OBJECTIVE: To provide an overview of the disease burden and current strategies in the treatment of patients with type 2 diabetes. DATA SOURCES: Medline search of all relevant clinical and review articles. STUDY SELECTION: By the author. DATA EXTRACTION: By the author. DATA SYNTHESIS: The prevalence of diabetes in the United States has reached epidemic proportions with the total diagnosed and undiagnosed cases among people aged 20 years or older estimated at 12.9%, and it continues to rise at an alarming rate. This upsurge has been paralleled by an increase in rates of obesity. Type 2 diabetes accounts for up to 95% of diabetes cases and is often comorbid with hypertension and dyslipidemia. CONCLUSION: Tight glycemic control is necessary for the management of type 2 diabetes, but progressive deterioration of beta-cell function can lead to a loss of glycemic control. Oral antidiabetes drugs and insulin are effective but do not always correct the associated metabolic and glucoregulatory dysfunctions, and hypoglycemia and weight gain are common adverse effects of these agents. A clear need exists for aggressive therapeutic options-particularly incretin-based agents-that can be combined with existing agents to preserve beta-cell function and halt the progression of type 2 diabetes.

Author information

Author/s: Campbell, R Keith (RK);

Affiliation: Dept. of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA 99164-6510, USA. rkcamp(-atsign-)wsu.edu

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: Journal of the American Pharmacists Association : JAPhA (J Am Pharm Assoc (2003)), published in United States. (Language: eng)

Reference: -2009 Sep-Oct; vol 49 Suppl 1 (issue ) : pp S3-9

Dates: Created 2009/10/05; Completed 2009/10/29;

PMID: 19801365, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Humans
Hypoglycemic Agents - adverse effects; therapeutic use
Incretins - metabolism
Insulin-Secreting Cells - drug effects; metabolism
Prevalence
Receptors, Glucagon - agonists
Time Factors
Treatment Outcome
Young Adult

Associated Chemicals: Blood Glucose (0) ; Dipeptidyl-Peptidase IV Inhibitors (0) ; Hemoglobin A, Glycosylated (0) ; Hypoglycemic Agents (0) ; Incretins (0) ; Receptors, Glucagon (0) ; glucagon-like peptide receptor (0) ; hemoglobin A1c protein, human (0) ; Antigens, CD26 (EC 3.4.14.5) ; DPP4 protein, human (EC 3.4.14.5)

These are the highest related articles currently in the database: